News

The company said that the revised labeling recognizes the capability of King’s enhanced processes to reduce Factor V light chain content to undetectable levels using currently available methodologies.

The study will enroll 300 patients with mild to moderate psoriasis at 20 investigational centers across the US. The placebo- and active-controlled study will evaluate three concentrations of

The company said that the goal of this Phase IIa study will be to optimize dosing in order to fully exploit the therapeutic potential of PRX302, while maintaining

Pfizer has included the three-year interim data from the postmenopausal evaluation and risk-reduction with lasofoxifene (PEARL) study in the current new drug application (NDA). Fablyn (lasofoxifene tartrate), formerly

Inspire has said that it is terminating the agreement in its entirety, and as a result, it will be no longer responsible for the development and commercialization of

Thelin (sitaxentan sodium) is indicated for improving exercise capacity in pulmonary arterial hypertension (PAH) patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown

In the non-inferiority study comparing risedronate 150mg once monthly to risedronate 5mg daily, increases in lumbar spine bone mineral density (BMD) at one year were similar for patients

The new offices will house the primary business operations of Zonda, including the office of Vera Leonard who serves as president and CEO of both Zonda and CLX

The company has also entered into a financial advisory agreement with EastGate Financial to provide consulting and advisory services with respect to establishing an office in New York,